Search

Your search keyword '"López-Martínez, Aurelio"' showing total 10 results
Start Over Author "López-Martínez, Aurelio"
10 results on '"López-Martínez, Aurelio"'

1. Immunoparesis recovery in newly diagnosed transplant ineligible multiple myeloma patients, an independent prognostic factor that complements minimal residual disease

Author

Lakhwani, Sunil, Mateos, María Victoria, Martínez-López, Joaquín, Paiva, Bruno, Rosiñol Dachs, Laura, Martínez, Rafael, Oriol, Albert, Bargay, Joan, González-Montes, Yolanda, Gironella, Mercedes, Encinas, Cristina, Martín, Jesús, Jarque, Isidro, Granell, Miquel, Abella, Eugenia, García-Mateo, Aránzazu, Hernández-Rivas, José Ángel, Ramila, Elena, Krsnik, Isabel, Casado Montero, Luis Felipe, De Arriba, Felipe, Palomera, Luis, Sampol, Antonia, Moraleda, José María, Casanova, María, Delgado, Pilar, Lafuente, Ana, Amutio, Elena, López-Martínez, Aurelio, Altés, Albert, Ruíz, M. Ángeles, Alegre, Adrián, Lopez-Anglada, Lucia, De La Cruz, Javier, Alonso Fernández, Rafael, Bladé Creixenti, Joan, Lahuerta, Juan-José, San-Miguel, Jesús, and Hernández, Miguel-Teodoro

Published
2024
Full Text
View/download PDF

2. Efficacy and Safety of CT-P10 Versus Rituximab in Untreated Low-Tumor-Burden Follicular Lymphoma: Final Results of a Randomized Phase III Study

Author

Kwak, Larry W., Sancho, Juan-Manuel, Cho, Seok-Goo, Nakazawa, Hideyuki, Suzumiya, Junji, Tumyan, Gayane, Kim, Jin Seok, Menne, Tobias, Mariz, José, Ilyin, Nikolai, Jurczak, Wojciech, Lopez Martinez, Aurelio, Samoilova, Olga, Zhavrid, Edvard, Yañez Ruiz, Eduardo, Trneny, Marek, Popplewell, Leslie, Ogura, Michinori, Kim, Won-Seog, Lee, Sang Joon, Kim, Sung Hyun, Ahn, Keum Young, and Buske, Christian

Published
2022
Full Text
View/download PDF

3. Chemotherapy or allogeneic transplantation in high-risk Philadelphia chromosome–negative adult lymphoblastic leukemia

Author

Ribera, Josep-Maria, Morgades, Mireia, Ciudad, Juana, Montesinos, Pau, Esteve, Jordi, Genescà, Eulàlia, Barba, Pere, Ribera, Jordi, García-Cadenas, Irene, Moreno, María José, Martínez-Carballeira, Daniel, Torrent, Anna, Martínez-Sánchez, Pilar, Monsalvo, Silvia, Gil, Cristina, Tormo, Mar, Artola, María Teresa, Cervera, Marta, González-Campos, José, Rodríguez, Carlos, Bermúdez, Arancha, Novo, Andrés, Soria, Beatriz, Coll, Rosa, Amigo, María-Luz, López-Martínez, Aurelio, Fernández-Martín, Rosa, Serrano, Josefina, Mercadal, Santiago, Cladera, Antònia, Giménez-Conca, Alberto, Peñarrubia, María-Jesús, Abella, Eugènia, Vall-llovera, Ferran, Hernández-Rivas, Jesús-María, Garcia-Guiñon, Antoni, Bergua, Juan-Miguel, de Rueda, Beatriz, Sánchez-Sánchez, María-José, Serrano, Alfons, Calbacho, María, Alonso, Natalia, Méndez-Sánchez, Jose-Ángel, García-Boyero, Raimundo, Olivares, Matxalen, Barrena, Susana, Zamora, Lurdes, Granada, Isabel, Lhermitte, Ludovic, Feliu, Evarist, and Orfao, Alberto

Published
2021
Full Text
View/download PDF

4. Efficacy, pharmacokinetics, and safety of the biosimilar CT-P10 in comparison with rituximab in patients with previously untreated low-tumour-burden follicular lymphoma: a randomised, double-blind, parallel-group, phase 3 trial

Author

Ogura, Michinori, Sancho, Juan Manuel, Cho, Seok-Goo, Nakazawa, Hideyuki, Suzumiya, Junji, Tumyan, Gayane, Kim, Jin Seok, Lennard, Anne, Mariz, José, Ilyin, Nikolai, Jurczak, Wojciech, Lopez Martinez, Aurelio, Samoilova, Olga, Zhavrid, Edvard, Yañez Ruiz, Eduardo, Trneny, Marek, Popplewell, Leslie, Coiffier, Bertrand, Buske, Christian, Kim, Won-Seog, Lee, Sang Joon, Lee, Sung Young, Bae, Yun Ju, and Kwak, Larry W

Published
2018
Full Text
View/download PDF

5. DIFFERENCES IN EX-VIVO CHEMOSENSITIVITY TO ANTHRACYCLINES IN FIRST LINE ACUTE MYELOID LEUKEMIA

Author

Megias-Vericat, Juan Eduardo, primary, Martínez-Cuadrón, David, primary, Martínez López, Joaquin, primary, Bergua, Juan Miguel, primary, Tormo, Mar, primary, Serrano, Josefina, primary, González, Ataulfo, primary, Pérez de Oteyza, Jaime, primary, Vives, Susana, primary, Vidriales, Belen, primary, Herrera, Pilar, primary, Vera, Juan Antonio, primary, López Martínez, Aurelio, primary, De la Fuente, Adolfo, primary, Amador, María Lourdes, primary, Hernández-Rivas, José Ángel, primary, Fernández, María Ángeles, primary, Cerveró, Carlos Javier, primary, Morillo, Daniel, primary, Hernández Campo, Pilar, primary, Gorrochategui, Julián, primary, Primo, Daniel, primary, Rojas, José Luis, primary, Guenova, Margarita, primary, Ballesteros, Joan, primary, Sanz, Miguel Ángel, primary, and Montesinos, Pau, primary

Published
2019
Full Text
View/download PDF

6. Efficacy and safety of native versus pegylated Escherichia coli asparaginase for treatment of adults with high-risk, Philadelphia chromosome-negative acute lymphoblastic leukemia

Author

Instituto de Salud Carlos III, Generalitat de Catalunya, Fundación la Caixa, Ribera, Josep-Maria, Morgades, Mireia, Montesinos, Pau, Martino, Rodrigo, Barba, Pere, Soria, Beatriz, Bermúdez, A., Moreno, María José, González-Campos, José A., Vives, Susana, Gil, Cristina, Abella, Eugènia, Guàrdia, Ramón, Martínez-Carballeira, Daniel, Martínez-Sánchez, Pilar, Amigo, María Luz, Mercadal, Santiago, Serrano, Alfons, López-Martínez, Aurelio, Vall‐Llovera, Ferran, Sánchez-Sánchez, María-José, Peñarrubia, María J., Calbacho, M., Méndez, Jose-Angel, Bergua, Juan, Cladera, Antonia, Tormo, Mar, García-Belmonte, Daniel, Feliu, Evarist, Ciudad, Juana, Orfao, Alberto, Instituto de Salud Carlos III, Generalitat de Catalunya, Fundación la Caixa, Ribera, Josep-Maria, Morgades, Mireia, Montesinos, Pau, Martino, Rodrigo, Barba, Pere, Soria, Beatriz, Bermúdez, A., Moreno, María José, González-Campos, José A., Vives, Susana, Gil, Cristina, Abella, Eugènia, Guàrdia, Ramón, Martínez-Carballeira, Daniel, Martínez-Sánchez, Pilar, Amigo, María Luz, Mercadal, Santiago, Serrano, Alfons, López-Martínez, Aurelio, Vall‐Llovera, Ferran, Sánchez-Sánchez, María-José, Peñarrubia, María J., Calbacho, M., Méndez, Jose-Angel, Bergua, Juan, Cladera, Antonia, Tormo, Mar, García-Belmonte, Daniel, Feliu, Evarist, Ciudad, Juana, and Orfao, Alberto

Abstract

Native or pegylated (PEG) asparaginase (ASP) are commonly used in treatment of acute lymphoblastic leukemia (ALL), but have been scarcely compared in the same trial in adult patients. Native vs. PEG-ASP administered according to availability in each center were prospectively evaluated in adults with high-risk ALL. Ninety-one patients received native ASP and 35 PEG-ASP in induction. No significant differences were observed in complete remission, minimal residual disease levels after induction and after consolidation, disease-free survival, and overall survival. No significant differences in grades 3–4 toxicity were observed in the induction period, although a trend for higher hepatic toxicity was observed in patients receiving PEG-ASP. In this trial the type of ASP did not influence patient response and outcome.

Published
2018

7. Comparison of Efficacy and Safety of Two Types of E.coli Asparaginase (Native or Pegylated) for Treatment of Adult Patients with High-Risk (HR), Philadelphia (Ph) Chromosome-Negative ALL Included in the Prospective MRD-Oriented Protocol ALL-HR-11 from the Spanish Pethema Group

Author

Ribera, Josep-Maria, primary, Morgades, Mireia, additional, Montesinos, Pau, additional, García-Cadenas, Irene, additional, Barba, Pere, additional, Soria, Beatriz, additional, Bermúdez, Arancha, additional, Moreno, MªJosé, additional, González-Campos, José, additional, Vives, Susana, additional, Gil, Cristina, additional, Abella, Eugenia, additional, Guàrdia, Ramon, additional, Bernal, Teresa, additional, Martínez-Sánchez, Pilar, additional, Amigo, MªLuz, additional, Mercadal, Santiago, additional, Serrano, Alfons, additional, López-Martínez, Aurelio, additional, Vall-llovera, Ferran, additional, Sánchez-Sánchez, MªJosé, additional, Peñarrubia, MªJesús, additional, Calbacho, María, additional, Méndez, Jose-Angel, additional, Bergua, Juan, additional, Cladera, Antònia, additional, Tormo, Mar, additional, García-Belmonte, Daniel, additional, Ciudad, Juana, additional, Feliu, Evarist, additional, and Orfao, Alberto, additional

Published
2016
Full Text
View/download PDF

8. Efficacy and safety of native versus pegylated Escherichia coli asparaginase for treatment of adults with high-risk, Philadelphia chromosome-negative acute lymphoblastic leukemia.

Author

Ribera, Josep-Maria, Morgades, Mireia, Montesinos, Pau, Martino, Rodrigo, Barba, Pere, Soria, Beatriz, Bermúdez, Arancha, Moreno, María-José, González-Campos, José, Vives, Susana, Gil, Cristina, Abella, Eugenia, Guàrdia, Ramon, Martínez-Carballeira, Daniel, Martínez-Sánchez, Pilar, Amigo, María-Luz, Mercadal, Santiago, Serrano, Alfons, López-Martínez, Aurelio, and Vall-Llovera, Ferran

Subjects
ASPARAGINASE, LYMPHOBLASTIC leukemia treatment, ESCHERICHIA coli, TREATMENT effectiveness, ADULTS, ERWINIA chrysanthemi, DRUG toxicity, DISEASE remission, MEDICAL care, THERAPEUTICS
Abstract

Native or pegylated (PEG) asparaginase (ASP) are commonly used in treatment of acute lymphoblastic leukemia (ALL), but have been scarcely compared in the same trial in adult patients. Native vs. PEG-ASP administered according to availability in each center were prospectively evaluated in adults with high-risk ALL. Ninety-one patients received native ASP and 35 PEG-ASP in induction. No significant differences were observed in complete remission, minimal residual disease levels after induction and after consolidation, disease-free survival, and overall survival. No significant differences in grades 3-4 toxicity were observed in the induction period, although a trend for higher hepatic toxicity was observed in patients receiving PEG-ASP. In this trial the type of ASP did not influence patient response and outcome. [ABSTRACT FROM AUTHOR]

Published
2018
Full Text
View/download PDF

10. Comparison of Efficacy and Safety of Two Types of E.coliAsparaginase (Native or Pegylated) for Treatment of Adult Patients with High-Risk (HR), Philadelphia (Ph) Chromosome-Negative ALL Included in the Prospective MRD-Oriented Protocol ALL-HR-11 from the Spanish Pethema Group

Author

Ribera, Josep-Maria, Morgades, Mireia, Montesinos, Pau, García-Cadenas, Irene, Barba, Pere, Soria, Beatriz, Bermúdez, Arancha, Moreno, MªJosé, González-Campos, José, Vives, Susana, Gil, Cristina, Abella, Eugenia, Guàrdia, Ramon, Bernal, Teresa, Martínez-Sánchez, Pilar, Amigo, MªLuz, Mercadal, Santiago, Serrano, Alfons, López-Martínez, Aurelio, Vall-llovera, Ferran, Sánchez-Sánchez, MªJosé, Peñarrubia, MªJesús, Calbacho, María, Méndez, Jose-Angel, Bergua, Juan, Cladera, Antònia, Tormo, Mar, García-Belmonte, Daniel, Ciudad, Juana, Feliu, Evarist, and Orfao, Alberto

Abstract

Background and objective. Asparaginase (ASP) is an essential drug for ALL treatment. Two types of E.coliASP (native and pegylated) are used in clinical trials for treatment of children and adults with ALL, but to our knowledge direct comparison between these two types of ASP in the same protocol has not been performed. This study aimed to compare the efficacy and safety of native vs. PEG-ASP in adult patients with HR, Ph-negative ALL.

Published
2016
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results